BioAtla Inc [BCAB] stock prices are up 1.26% to $1.61 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BCAB shares have gain 2.55% over the last week, with a monthly amount drifted -19.50%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BioAtla Inc [NASDAQ: BCAB] stock has seen the most recent analyst activity on November 13, 2024, when H.C. Wainwright downgraded its rating to a Neutral. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 15, 2022, and set its price target to $17. On May 05, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $5 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $25 on March 21, 2022. ROTH Capital started tracking with a Buy rating for this stock on June 28, 2021, and assigned it a price target of $75.
The stock price of BioAtla Inc [BCAB] has been fluctuating between $1.14 and $4.02 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. BioAtla Inc [NASDAQ: BCAB] shares were valued at $1.61 at the most recent close of the market. An investor can expect a potential return of 210.56% based on the average BCAB price forecast.
Analyzing the BCAB fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -6.79%, Pretax Profit Margin comes in at -6.44%, and Net Profit Margin reading is -6.44%. To continue investigating profitability, this company’s Return on Assets is posted at -1.31, Equity is -1.87 and Total Capital is -2.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5633 points at the first support level, and at 1.5167 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6833, and for the 2nd resistance point, it is at 1.7567.
Ratios To Look Out For
It’s worth pointing out that BioAtla Inc [NASDAQ:BCAB]’s Current Ratio is 3.11. Also, the Quick Ratio is 3.11, while the Cash Ratio stands at 2.9. Considering the valuation of this stock, the price to sales ratio is 7.08, the price to book ratio is 3.39.
Transactions by insiders
Recent insider trading involved MCBRINN SYLVIA, Director, that happened on Dec 26 ’23 when 4000.0 shares were purchased. Chief Executive Officer, SHORT JAY M PHD completed a deal on Dec 20 ’23 to buy 50000.0 shares. Meanwhile, Director STEINMAN LAWRENCE bought 20000.0 shares on Dec 19 ’23.
